Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant
The IAP antagonist Is In Phase III Trials For Head And Neck Cancer
• By Sten Stovall
Merck will use its expertise in head and neck cancer to advance xevinapant. • Source: Shutterstock 
